Fig. 2: Transglutaminase-2 expression is associated with decreased patient survival.
From: Transglutaminase-2 facilitates extracellular vesicle-mediated establishment of the metastatic niche
a Transcript levels for TGM2 in HME2 parental, TGF-β1 treated (TGFB), and bone metastases (BM) were quantified using qRT-PCR. Data are expressed relative to HME2-parental cells and are the mean ± SE of three independent experiments resulting in the indicated p values. b Immunoblot analyses for TG2, FN1, and E-cadherin (Ecad) in HME2 parental, TGF-β1 treated (TGFB), and bone metastases (BM). Expression of β-tubulin served as a loading control. Data are representative of at least three independent experiments. c Densitometric analyses of the immunoblots described in b. d Comparison of overall survival between patients bearing grade 3 tumors expressing levels of TG2 and FN above (high) or below (low) the mean of the entire patient cohort. Survival curves were analyzed via a log-rank test resulting in the indicated p values.
